Skip to main content
. 2023 Apr 6;14:1129465. doi: 10.3389/fimmu.2023.1129465

Figure 2.

Figure 2

The incidence of secondary resistance to immunotherapy in NSCLC patients. ICIs applied as first- and second-line treatment in treating NSCLC patients resulted in 52%-57% and 32%-64% rates of secondary resistance, respectively. MSKCC found that 78% of patients who acquired an initial response to PD-1 inhibitors further developed secondary resistance.